GSK Tops List With Most Drugs Exempt From Biennial Re-Pricing In Japan
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline Plc had the most drugs exempt from Japan’s drug re-pricing policy implemented every other year.